Published :
Tables : 43
Figures : 41
Category : Healthcare
No. of Pages : 210
Report Code : HC-1193
Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market is estimated to value over CAGR of over 5.2% during the forecast period 2022 to 2028. Acute lymphocytic/lymphoblastic Leukaemia (ALL) is a type of cancer that is developed from immature lymphocytes. ALL usually develops in the bone marrow and it quickly invades other body parts like the spleen, lymph nodes, liver, central nervous system and the blood. There can be non-specific symptoms and may include feeling tired and weak, bruises, paler skin, nose bleeds, severe and frequent bleeding gums; shortness of breath, weight loss and loss of appetite. Different therapeutics are used for ALL treatment. Based on drug, the acute lymphocytic/lymphoblastic Leukaemia (ALL) market is divided into Hyper-CVAD Regimen, Linker Regimen, Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), and Oncaspar. Furthermore, targeted drugs & immunotherapy are predicted to grow at the fastest growth rate during the forecast period as it is widely used in patients who do not respond to chemotherapy and these drugs have shown immense potential in the relapsed acute lymphocytic leukaemia treatment. Therefore, these factors contribute to the acute lymphocytic/lymphoblastic leukaemia (ALL) market growth. North America occupied the largest acute lymphocytic/lymphoblastic Leukaemia (ALL) market share in 2018 and is projected to maintain its lead over the forecast period due to high cost of treatments, easy availability of treatments, and presence of a majority of key players. Nonetheless, the Asia-Pacific is expected to exhibit the highest growth rate during the forecast period, owing to a rise in patient awareness towards cancer care and high population base. Key market players are Erytech Pharma, Spectrum Pharmaceuticals Inc., Genman A/S, Bristol-Myers Squibb Company, Genzyme Corp. (Sanofi), Pfizer Inc., Sigma-tau spa, Novartis AG, Celegene Corp., Juno Therapeutics Inc. Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Segmentation: By Therapy Chemotherapy Hyper-CVAD CALGB 8811 Regimen Linker Regimen Nucleoside Metabolic Inhibitors Oncaspar Targeted Therapy Radiation Therapy Stem Cell Transplantation By Type Philadelphia Chromosome Positive Ph (Ph+) Negative Ph (Ph-) Precursor B-Cell ALL T-Cell ALL By Region North America Europe Asia Pacific Latin America Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global acute lymphocytic/lymphoblastic Leukaemia (ALL) therapeutics market by product, by type and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Acute lymphocytic/lymphoblastic Leukaemia (ALL) is a type of cancer that is developed from immature lymphocytes. ALL usually develops in the bone marrow and it quickly invades other body parts like the spleen, lymph nodes, liver, central nervous system and the blood. There can be non-specific symptoms and may include feeling tired and weak, bruises, paler skin, nose bleeds, severe and frequent bleeding gums; shortness of breath, weight loss and loss of appetite. Different therapeutics are used for ALL treatment. Based on drug, the acute lymphocytic/lymphoblastic Leukaemia (ALL) market is divided into Hyper-CVAD Regimen, Linker Regimen, Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), and Oncaspar.
Furthermore, targeted drugs & immunotherapy are predicted to grow at the fastest growth rate during the forecast period as it is widely used in patients who do not respond to chemotherapy and these drugs have shown immense potential in the relapsed acute lymphocytic leukaemia treatment. Therefore, these factors contribute to the acute lymphocytic/lymphoblastic leukaemia (ALL) market growth. North America occupied the largest acute lymphocytic/lymphoblastic Leukaemia (ALL) market share in 2018 and is projected to maintain its lead over the forecast period due to high cost of treatments, easy availability of treatments, and presence of a majority of key players. Nonetheless, the Asia-Pacific is expected to exhibit the highest growth rate during the forecast period, owing to a rise in patient awareness towards cancer care and high population base.
Key market players are Erytech Pharma, Spectrum Pharmaceuticals Inc., Genman A/S, Bristol-Myers Squibb Company, Genzyme Corp. (Sanofi), Pfizer Inc., Sigma-tau spa, Novartis AG, Celegene Corp., Juno Therapeutics Inc.
Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Segmentation:
By Therapy
By Type
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Type Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Type Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Type Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market, By therapy Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Chemotherapy 7.1.1. Hyper-CVAD 7.1.2. CALGB 8811 Regimen 7.1.3. Linker Regimen 7.1.4. Nucleoside Metabolic Inhibitors 7.1.5. Oncaspar 7.2. Targeted Therapy 7.3. Radiation Therapy 7.4. Stem Cell Transplantation 8. Global Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market, By type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Philadelphia Chromosome 8.2. Positive Ph (Ph+) 8.3. Negative Ph (Ph-) 8.4. Precursor B-Cell ALL 8.5. T-Cell ALL 9. North America Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028 10. Latin America Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2028 11. Europe Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2028 12. Asia Pacific Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028 14. Market Share Analysis and Competitive Landscape 14.1. Global Landscape - Key Players, Revenue and Presence 14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 14.3. Global Emerging Companies 14.4. North America - Market Share Analysis and Key Regional Players 14.5. Europe - Market Share Analysis and Key Regional Players 14.6. Asia Pacific - Market Share Analysis and Key Regional Players 14.7. Global Key Player - Growth Matrix 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 15.1. Erytech Pharma. 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Spectrum Pharmaceuticals Inc. 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Genmab A/S 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Bristol-Myers Squibb Company 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Genzyme Corporation (Sanofi) 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Pfizer, Inc. 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Sigma-tau spa 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Novartis AG 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Celgene Corporation 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. Juno Therapeutics, Inc. 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Type Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Type Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Type Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market, By therapy Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Chemotherapy 7.1.1. Hyper-CVAD 7.1.2. CALGB 8811 Regimen 7.1.3. Linker Regimen 7.1.4. Nucleoside Metabolic Inhibitors 7.1.5. Oncaspar 7.2. Targeted Therapy 7.3. Radiation Therapy 7.4. Stem Cell Transplantation
8. Global Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market, By type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Philadelphia Chromosome 8.2. Positive Ph (Ph+) 8.3. Negative Ph (Ph-) 8.4. Precursor B-Cell ALL 8.5. T-Cell ALL
9. North America Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028
10. Latin America Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2028
11. Europe Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2028
12. Asia Pacific Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028
14. Market Share Analysis and Competitive Landscape 14.1. Global Landscape - Key Players, Revenue and Presence 14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 14.3. Global Emerging Companies 14.4. North America - Market Share Analysis and Key Regional Players 14.5. Europe - Market Share Analysis and Key Regional Players 14.6. Asia Pacific - Market Share Analysis and Key Regional Players 14.7. Global Key Player - Growth Matrix
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 15.1. Erytech Pharma. 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Spectrum Pharmaceuticals Inc. 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Genmab A/S 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Bristol-Myers Squibb Company 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Genzyme Corporation (Sanofi) 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Pfizer, Inc. 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Sigma-tau spa 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Novartis AG 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Celgene Corporation 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. Juno Therapeutics, Inc. 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview
16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations
17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics